Among the 16 valuable biomarkers, 11 highly elevated genes in the high‐risk group, including SMC4, HEXB, VAV3, E2F7, EFNB1, WEE1, SAA1, SHISA5, PSMC2, PTGFRN and HMGA2, were significantly associated with poor outcome for patients with gliomas. This evidence concerns the gene SMC4 and central nervous system cancer.